- Conditions
- Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Cancer of the Breast
- Interventions
- IPI-504, Trastuzumab
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 10
- States / cities
- Palm Springs, California • Boca Raton, Florida • Davie, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 848
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
- Interventions
- DC1 Vaccine, WOKVAC Vaccine
- Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 4 more
- Conditions
- Brest Cancer ER+ and HER2 Negative
- Interventions
- Letrozole
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 59 Years · Female only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Breast Cancer
- Interventions
- neratinib, placebo
- Drug · Other
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 185
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 147 more
- Conditions
- Her2 Amplified Solid Tumors, Metastatic Breast Cancer
- Interventions
- MM-111
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
- Conditions
- Breast Cancer
- Interventions
- D-0502, palbociclib
- Drug
- Lead sponsor
- InventisBio Co., Ltd
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 11
- States / cities
- Fresno, California • Aurora, Colorado • New Haven, Connecticut + 7 more
- Conditions
- Advanced HER2-positive Breast Cancer
- Interventions
- AUY922, Trastuzumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Breast Neoplasms, Breast Cancer
- Interventions
- Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 8
- States / cities
- Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
- Conditions
- Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
- Interventions
- Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri
- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
- Interventions
- Palbociclib, Olaparib, Fulvestrant
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Crofelemer
- Drug
- Lead sponsor
- Sandra Swain
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey
- Conditions
- Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Tumors Metastatic to Brain
- Interventions
- lapatinib ditosylate, laboratory biomarker analysis, quality-of-life assessment, questionnaire administration
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Stage IV Breast Cancer
- Interventions
- positron emission tomography, copper Cu 64-DOTA-trastuzumab, Biopsy, Immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis
- Procedure · Radiation · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- HER-2/neu peptide vaccine
- Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Paclitaxel, Trastuzumab
- Other · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2024
- U.S. locations
- 317
- States / cities
- Tucson, Arizona • Fort Smith, Arkansas • Burbank, California + 222 more
- Conditions
- Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
- Interventions
- ZB716, Palbociclib
- Drug
- Lead sponsor
- EnhancedBio USA Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer
- Interventions
- A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physician's choice
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Interventions
- Fulvestrant, Anastrozole, Abemaciclib
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, Docetaxel, epirubicin hydrochloride, fluorouracil, ixabepilone
- Drug
- Lead sponsor
- UNICANCER
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 762 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Jacksonville, Florida + 14 more
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Cancer, Cancer Metastatic
- Interventions
- Trastuzumab Deruxtecan, Stereotactic Radiosurgery
- Drug · Radiation
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer, Early Stage Breast Cancer
- Interventions
- There are no interventions in this observational study.
- Other
- Lead sponsor
- Tempus AI
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Whittier, California • Weston, Florida + 13 more
- Conditions
- Breast Cancer
- Interventions
- Paclitaxel, Trastuzumab, Pertuzumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole
- Drug
- Lead sponsor
- Celcuity Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 30
- States / cities
- Jonesboro, Arkansas • Little Rock, Arkansas • Duarte, California + 27 more
- Conditions
- Breast Neoplasms
- Interventions
- Imlunestrant, Goserelin, Tamoxifen 20 mg
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 27 more